Kelonia is developing technology to reprogram patients’ T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Source: CNBC World
Eli Lilly Agrees to Acquire Cancer Drug Maker Kelonia in Deal Worth up to $7 Billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.